Testosterone Replacement Therapy: A Narrative Review with a Focus on New Oral Formulations.
Ontology highlight
ABSTRACT: Male hypogonadism affects 10-30% of the male population and is often under-recognized and under-treated. Different replacement formulations exist, each with specific benefits and limitations. These replacements include gels, patches and short- and long-acting injectables. JATENZO® (oral testosterone undecanoate; Clarus Therapeutics Inc., Northbrook, IL, US) is the first oral formulation of testosterone approved by the US Food and Drug Administration. TLANDO® (oral testosterone undecanoate; Lipocine Inc., Salt Lake City, UT, US), another oral testosterone formulation, has also recently been approved by the US Food and Drug Administration. Based on unique chemistry using a self-emulsifying drug delivery system and lymphatic absorption, JATENZO and TLANDO address some of the limitations of ot
SUBMITTER: Bhat SZ
PROVIDER: S-EPMC9835814 | biostudies-literature | 2022 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA